PYC Therapeutics Shares Pull Back From Highs, As Momentum Tested

PYC Therapeutics shares (ASX: PYC) fell back sharply today, down 7.84% to close at A$2.47. The pullback tests a near-term technical level for a stock that has been one of the index’s standout performers over the past year, with a more than 2x return.

This latest pullback continues a cooling period that began two weeks ago when PYC shares reached decade highs of A$2.93, pushing the stock’s RSI into overbought territory. Since that high however, the stock has given back 15.7%, with today’s move pushing the share price below the 30-day SMA of A$2.52, a near-term momentum watch point of support.

Despite the recent softness, PYC shares are up 52.47% since the start of the year, and have more than doubled over the past twelve months, gaining 107.6%. The stock also continues to trade well above its 50-day SMA at A$2.33, which represents the next meaningful support level should selling pressure persist. With the RSI now sitting at a neutral 48.1, the technical froth has faded, potentially setting the stage for a momentum test for bulls.

Driving Recent Price Action in PYC

The recent run in PYC shares has been supported by a series of developments that have taken some risk off the table as far as the company’s investment case. Most significantly, PYC announced initial exploratory efficacy data for its lead drug candidate PYC-003, which targets Autosomal Dominant Polycystic Kidney Disease (ADPKD). In single-dose Phase 1a/1b studies involving seven cohort subjects, PYC-003 demonstrated a 46% mean increase in urinary PC1 protein levels at Day 14 compared to baseline.

In late Q3 2026, PYC dosed its first patient in an Open-Label Extension (OLE) study for PYC-003, transitioning patients who completed the main multiple-ascending dose (MAD) trial into a continuous dosing protocol designed to generate long-term safety and tolerability data. This shift signals an organisational maturation from early-stage discovery into late-stage clinical execution, a transition PYC has supported with senior executive hires including a Chief Clinical Development Officer and a Head of Regulatory Affairs.

Looking ahead, the company is scheduled to present expanded exploratory data at the American Society of Nephrology (ASN) Conference in Denver in a couple of weeks time (October 22), setting the stage for a binary catalyst. TKV is a validated surrogate endpoint in ADPKD trials and is closely watched by nephrologists and drug developers alike.

PYC was also officially added to the ASX 300 Index during the September 2026 rebalance, a recognition of its rapid market capitalisation expansion that brought increased institutional liquidity and broader analyst coverage to the stock.

What Next?

The question now is whether the pullback represents a technical reset within an uptrend or the early stages of a consolidation phase.

From a technical standpoint, the break below the 30-day SMA at A$2.52 is a mild negative signal but not an alarm. The 50-day SMA at A$2.33 provides a deeper layer of structural support, and the RSI’s return to neutral territory at 48.1 removes the overbought overhang that made the stock vulnerable to profit-taking. A decisive close back above A$2.52 would reassert short-term momentum.

The fundamental picture turns to the ASN presentation on October 22 as a binary risk, where a strong TKV dataset across 18 patients could reignite the rally, while disappointing or inconclusive data would likely extend the current weakness. The full Phase 1b efficacy dataset is not expected until 2027, and registrational Phase 3 trials are not anticipated to commence until approximately 2028, underscoring the long commercialisation runway that remains ahead.

With some of the initial pop from the ASX 300 addition fading, a period of consolidation heading into the next data sets is not a bad thing in the grand scheme of things. Bulls will be eager to see the stock regain momentum before long, yet a glance at the chart shows a clear uptrend with higher highs and higher lows.